InStent EndoCoil biliary stent is awaiting 510(k) clearance -- IPO.

This article was originally published in The Gray Sheet

05 Jun 1995
News

Executive Summary

INSTENT ENDOCOIL STENT FOR MALIGNANT BILIARY STRICTURES due to pancreatic cancer is awaiting 510(k) clearance by FDA, the firm notes in a registration statement filed with the Securities and Exchange Commission for an initial public offering. The company "has responded to requests from FDA for additional information" on the 510(k) and "is currently awaiting FDA action," the filing states.

Already Registered? Sign in to continue reading.

New to Medtech Insight? Start a free trial today!

Table
View full table

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

MT004185

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

MT004185

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

InStent EndoCoil biliary stent is awaiting 510(k) clearance -- IPO.

News

Executive Summary

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert